Vivoryon Therapeutics N.V.

Equities

VVY

NL00150002Q7

Biotechnology & Medical Research

Market Closed - Euronext Amsterdam Other stock markets 11:35:14 2024-05-03 am EDT			5-day change	1st Jan Change
0.761 ^EUR	+7.18%		-4.88%	-90.65%

Apr. 24	Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024
Mar. 15	Vivoryon Therapeutics N.V Announces Resignation of Board of Directors	CI

Vivoryon Therapeutics N : Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates

April 24, 2024 at 04:06 am EDT

Vivoryon Therapeutics N.V.

Vivoryon Therapeutics N.V.

Below you will find information from the register publication of inside information. The information has been provided by the organisation.

Registration date24 apr 2024 - 07:12

Statutory nameVivoryon Therapeutics N.V.

TitleVivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates

Previous result

Next result

Related downloads

202404240000000004_vvy-ye23-earnings-release.pdf(opens in a new window)

Date last update: 24 April 2024

Attachments

Original Link
Permalink

Disclaimer

Vivoryon Therapeutics NV published this content on 24 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 April 2024 08:05:04 UTC.

Latest news about Vivoryon Therapeutics N.V.

Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024	Apr. 24
Vivoryon Therapeutics N.V Announces Resignation of Board of Directors	Mar. 15	CI
Vivoryon Therapeutics N.V. Provides Update on Viviad Phase 2B Study of Varoglutamstat in Early Alzheimer?S Disease	Mar. 04	CI
Transcript : Vivoryon Therapeutics N.V., Q3 2023 Earnings Call, Dec 06, 2023	Dec. 06
Vivoryon Therapeutics N.V. Announces Executive Changes	Dec. 06	CI
Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision	23-10-26	CI
Transcript : Vivoryon Therapeutics N.V. - Special Call	23-10-17
Vivoryon Therapeutics N.V. Announces Board Appointments	23-09-15	CI
Transcript : Vivoryon Therapeutics N.V., H1 2023 Earnings Call, Sep 07, 2023	23-09-07
Vivoryon Therapeutics N.V. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-07	CI
Certain Shares of Vivoryon Therapeutics N.V. are subject to a Lock-Up Agreement Ending on 24-AUG-2023.	23-08-23	CI
Vivoryon Therapeutics Promotes Chief Medical Officer to CEO	23-08-07	MT
Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimerâ€™s Disease	23-07-16	CI
Vivoryon Therapeutics N.V. Approves Board Appointments	23-06-21	CI
Vivoryon Therapeutics CEO to Step Down in FY24	23-06-16	MT
Vivoryon Therapeutics N.V. Announces Resignation of Ulrich Dauer as CEO	23-06-15	CI
Vivoryon Rises 7% on EUR25 Million Capital Raise	23-05-26	MT
Vivoryon Therapeutics N.V. Announces Resignation of Dinnies Johannes Von Der Osten, PhD, and Jörg Neermann, PhD from the Board of Directors	23-05-01	CI
Transcript : Vivoryon Therapeutics N.V., Q4 2022 Earnings Call, Apr 19, 2023	23-04-19
Vivoryon Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-19	CI
Vivoryon Therapeutics N.V. Auditor Raises 'Going Concern' Doubt	23-04-18	CI
Vivoryon Therapeutics N.V. Provides Progress Update on Varoglutamstat Clinical Development for the Treatment of Alzheimer's Disease	23-03-28	CI
Transcript : Vivoryon Therapeutics N.V. Presents at Barclays Global Healthcare Conference, Mar-16-2023 08:00 AM	23-03-16
Transcript : Vivoryon Therapeutics N.V., Q3 2022 Earnings Call, Nov 22, 2022	22-11-22
Transcript : Vivoryon Therapeutics N.V., H1 2022 Earnings Call, Sep 30, 2022	22-09-30

Chart Vivoryon Therapeutics N.V.

Duration

Period

More charts

Company Profile

Vivoryon Therapeutics N.V. specializes in the research and development of therapeutic products for the treatment of Alzheimer disease. At the end of 2022, the group has a portfolio of a product in phase II clinical development (Varoglutamstat; PQ912) and 2 products in the preclinical development phase.

Sector

Biotechnology & Medical Research

Calendar

2024-06-11 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.761 EUR

Average target price

41.57 EUR

Spread / Average Target

+5,362.11%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VIVORYON THERAPEUTICS N.V.	-90.65%	21.37M
MODERNA, INC.	+25.69%	47.86B
LONZA GROUP AG	+46.90%	41.42B
IQVIA HOLDINGS INC.	-3.46%	40.66B
CELLTRION, INC.	-6.20%	28.92B
ICON PUBLIC LIMITED COMPANY	+9.17%	25.55B
ALNYLAM PHARMACEUTICALS, INC.	-20.42%	19.27B
MEDPACE HOLDINGS, INC.	+28.07%	12.14B
BIO-TECHNE CORPORATION	+0.17%	12.15B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.24%	11.99B

Other Biotechnology & Medical Research